--- title: "07:03 ET Life Sciences Leaders Advance Unified Engagement at Veeva Commercial Summit" type: "News" locale: "en" url: "https://longbridge.com/en/news/238894287.md" description: "Veeva Systems (NYSE: VEEV) announced keynote speakers for the 2025 Veeva Commercial Summit, scheduled for May 13-14 in Boston. The summit will feature leaders from AstraZeneca, Bayer, Boehringer Ingelheim, and Eli Lilly, sharing strategies for enhanced customer engagement through AI and data alignment. Veeva CEO Peter Gassner will present the company's initiative to integrate AI into its platforms. The event aims to unite industry professionals to discuss advancements in commercial and medical affairs." datetime: "2025-05-06T11:03:41.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/238894287.md) - [en](https://longbridge.com/en/news/238894287.md) - [zh-HK](https://longbridge.com/zh-HK/news/238894287.md) --- # 07:03 ET Life Sciences Leaders Advance Unified Engagement at Veeva Commercial Summit _AstraZeneca, Bayer, Boehringer Ingelheim, Eli Lilly and Company, and more share strategies for more connected customer experiences across sales, marketing, and medical_ , /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced its keynote speakers for the 2025 Veeva Commercial Summit, May 13-14 in Boston. Leading and emerging biopharmas will share innovations and strategies to drive more coordinated customer engagement through effective use of AI and alignment across data, content, and teams. Veeva CEO Peter Gassner will headline the opening keynote, sharing Veeva's major initiative to add AI to the Vault Platform and Veeva applications, including ongoing innovations across Veeva Commercial Cloud and Veeva Data Cloud. Keynote presenters will include experiences from: - **AstraZeneca** standardizing analytics across its brands to boost marketing reach and performance. - **Bayer** driving customer-centric, coordinated engagement with Vault CRM. - **Boehringer Ingelheim** connecting scientific insights across medical to drive effective, personalized key opinion leader conversations. - **Lilly** integrating its content ecosystem by streamlining workflows, standardizing taxonomy, and aligning global teams to deliver high-impact experiences at scale. - **Johnson & Johnson** and **Madrigal** each building a modern data foundation with connected insights for greater efficiency and field impact. ANI Pharmaceuticals, Gamida Cell, NewAmsterdam Pharma, Orchard Therapeutics, Sobi, and others will also share go-to-market best practices for emerging biotechs at launch and beyond. "By connecting sales, marketing, and medical, field teams can seamlessly work together to drive more effective, customer-centric experiences," said Matt Farrell, president of Veeva Commercial Cloud. "We're excited to bring the industry together to share ideas and advancements in AI and data and help lead this next phase of unified engagement." Veeva Commercial Summit is one of the largest industry events in North America for commercial and medical affairs leaders. Life sciences industry professionals can register and see the full agenda at veeva.com/Summit. **About Veeva Systems **Veeva is the global leader in cloud software for the life sciences industry. Committed to innovation, product excellence, and customer success, Veeva serves more than 1,000 customers, ranging from the world's largest biopharmaceutical companies to emerging biotechs. As a Public Benefit Corporation, Veeva is committed to balancing the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves. For more information, visit veeva.com. **Veeva Forward-looking Statements **This release contains forward-looking statements regarding Veeva's products and services and the expected results or benefits from use of our products and services. These statements are based on our current expectations. Actual results could differ materially from those provided in this release and we have no obligation to update such statements. There are numerous risks that have the potential to negatively impact our results, including the risks and uncertainties disclosed in our filing on Form 10-K for the fiscal year ended January 31, 2025, which you can find here (a summary of risks which may impact our business can be found on pages 9 and 10), and in our subsequent SEC filings, which you can access at sec.gov. **Contact:** Matilde Macieira-Kaufmann Veeva Systems 925-226-8821 \[email protected\] SOURCE Veeva Systems ### Related Stocks - [VEEV.US](https://longbridge.com/en/quote/VEEV.US.md) - [LLY.US](https://longbridge.com/en/quote/LLY.US.md) ## Related News & Research - [Veeva Systems (VEEV) Stock After 43% Slide Are DCF Expectations Too High](https://longbridge.com/en/news/289673981.md) - [07:00 ETUCB Transforms Safety Operations with Veeva Safety Suite in Collaboration with ELIQUENT Life Sciences, Pinnaxis, and Daelight Solutions](https://longbridge.com/en/news/289586925.md) - [02:22 ETUCB vereinheitlicht seine weltweiten Pharmakovigilanz-Aktivitäten mit der Veeva Safety Suite](https://longbridge.com/en/news/289281064.md) - [UCB Unifies Global Pharmacovigilance Operations with Veeva Safety Suite | VEEV Stock News](https://longbridge.com/en/news/289179021.md) - [Merck KGaA, Darmstadt, Germany Selects Veeva Vault CRM Worldwide | VEEV Stock News](https://longbridge.com/en/news/287759763.md)